Spironolactone and hydrochlorothiazide decrease vascular stiffness and blood pressure in geriatric hypertension

Journal of the American Geriatrics Society

Volumn 58, Issue 7, 2010, Pages 1327-1332

  Kithas, Philip A ^a,b   Supiano, Mark A ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

aldosterone; ambulatory blood pressure monitoring; pulse wave velocity; vascular stiffness

Indexed keywords

ALDOSTERONE; HYDROCHLOROTHIAZIDE; RENIN; SPIRONOLACTONE;

AGED; ALDOSTERONE BLOOD LEVEL; ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE REGULATION; CAROTID ARTERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG TARGETING; FEMALE; FEMORAL ARTERY; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; PULSE PRESSURE; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE;

AGE FACTORS; AGED; ALDOSTERONE ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BLOOD FLOW VELOCITY; BLOOD PRESSURE MONITORING, AMBULATORY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; SPIRONOLACTONE; TREATMENT OUTCOME; VASODILATION;

EID: 77954324475     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2010.02905.x     Document Type: Article

References (26)

1. Chobanian AV. Isolated systolic hypertension in the elderly. N Engl J Med 2007 357 : 789 796.
2. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med 2009 150 : 776 783.
3. Sengstock DM, Vaitkevicius PV, Supiano MA. Arterial stiffness is related to insulin resistance in nondiabetic hypertensive older adults. J Clin Endocrinol Metab 2005 90 : 2823 2827.
4. Vasan RS, Evans JC, Larson MG et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004 351 : 33 41.
5. Brown NJ. Aldosterone and vascular inflammation. Hypertension 2008 51 : 161 167.
6. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension 2006 47 : 312 318.
7. Williams JS, Williams GH. 50th anniversary of aldosterone. J Clin Endocrinol Metab 2003 88 : 2364 2372.
8. Schrijver G, Weinberger MH. Hydrochlorothiazide and spironolactone in hypertension. Clin Pharmacol Ther 1979 25 : 33 42.
9. Puig JG, Miranda ME, Mateos F et al. Hydrochlorothiazide versus spironolactone: Long-term metabolic modifications in patients with essential hypertension. J Clin Pharmacol 1991 31 : 455 461.
10. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999 341 : 709 717.
11. Pitt B, Remme W. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003 348 : 1309 1321.
12. Wei Y, Whaley-Connell AT, Habibi J et al. Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation. Hypertension 2009 53 : 158 165.
13. White WB, Duprez D, St Hillaire R et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003 41 : 1021 1026.
14. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003 42 : 1206 1252.
15. Appel LJ. The verdict from ALLHAT-thiazide diuretics are the preferred initial therapy for hypertension. JAMA 2002 288 : 3039 3042.
16. Siscovick DS, Raghunathan TE, Psaty BM et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994 330 : 1852 1857.
17. Mahmud A, Feely J. Effect of angiotensin II receptor blockade on arterial stiffness: Beyond blood pressure reduction. Am J Hypertension 2002 15 : 1092 1095.
18. Mackenzie IS, McEniery CM, Dhakam Z et al. Comparison of the effects of antihypertensive agents on central blood pressure and arterial stiffness in isolated systolic hypertension. Hypertension 2009 54 : 409 413.
19. Boutouyrie P, Tropeano AI, Asmar R et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients. A longitudinal study. Hypertension 2002 39 : 10 15.
20. Hansen TW, Staessen JA, Torp-Pedersen C et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006 113 : 664 670.
21. McEniery CM, Yasmin, Hall IR et al. Normal vascular aging: Differential effects on wave reflection and aortic pulse wave velocity. The Anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Card 2005 46 : 1753 1760.
22. Clement DL, De Buyzere ML, De Bacquer DA et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003 348 : 2407 2415.
23. Bjorklund K, Lind L, Zethelius B et al. Prognostic significance of 24-h ambulatory blood pressure characteristics for cardiovascular morbidity in a population of elderly men. J Hypertension 2004 22 : 1691 1697.
24. Staessen JA, Thijs L, Fagard R et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA 1999 282 : 539 546.
25. Ohkubo T, Hozawa A, Yamaguchi J et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: The Ohasama study. J Hypertension 2002 20 : 2183 2189.
26. Kario K, Pickering TG, Umeda Y et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: A prospective study. Circulation 2003 107 : 1401 1406.